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Purpose/Objective: To assess the role of an intraoperative 
electron boost (IOERT) in combination with hypofractionated 
whole breast irradiation (WBI) in terms of in-breast tumor 
control and cosmetic outcome. 
Materials and Methods: Starting in Jan 2011, a prospective 
multi-center single arm trial is conducted by the ISIORT. 
Patients receive an IOERT boost of 10 Gy (Dmax 11.1 Gy) 
followed by a WBI of 40.5 Gy in 15 fractions (2.7 Gy single 
dose). 5-year in-breast-recurrence rates will be analyzed in 3 
different age groups (35-40 y, 41-50 y, > 50y) and tested 
against the respective best published results from 
randomized prospective trials by the use of a sequential 
probability ratio test (SPRT). Acute reactions are assessed by 
CTC-scoring, late reactions according to LENT-SOMA criteria. 
Cosmesis is evaluated by a 5-point-Scoring System (van 
Limbergen, double evaluation) starting prior to WBI on the 
basis of repeated photodocumentation in standardized 
positions. 
Results: As of August 2014, within ten active institutions 645 
patients have been recruited, 481 of them already in follow-
up. Patient and tumor characteristics are summarized in 
Table 1. For IOERT, the median energy chosen was 7 MeV 
(range 4-12) with median tube diameters of 6 cm (4-8) and 
mean prescription depths of 19 mm (6.2 SD), resulting in 
mean D90 volumes of 19 ml. Perioperatively, no major 
complications were observed. Four weeks after the end of 
WBI and 479 evaluated patients, 177 (37%) showed no 
reactions (CTC 0), 277 (58%) presented with faint (CTC 1) and 
24 (5%) with moderate to brisk erythema (CTC 2), 
respectively. Go-I late reactions (LENT-SOMA) occured in a 
mean frequency of 97%, 96%, 98% and 96% after 4-5 
months,1,2 and 3 years follow-up, respectively. Cosmesis was 
assessed postoperatively by patients themselves (subjective) 
and doctors (objective). Baseline appearance was first 
assessed after wound healing prior to WBI and scored as 
sufficient (excellent and good) in 69%/74% of 614 
subjective/447 objective evaluations. Respective results at 4-
5 months, one, two and three years post RT were 87%/75% of 
418/378, 89%/77% of 306/164, 83%/75% of 132/107 and 
84%/87.5% of 31/24 ratings. At a median follow-up period of 
12.6 months (range 0.5-37), three patients were 
metastasized, two died, no in-breast recurrence was noted. 
Tab.1 Patient characteristics  
 
Patient age (y) n  Histology  n  
35-40 15  IDC  416 
41-50 120  ILC  50  
> 50 405  mixed  46  
T-stage 
 
mucinous 8  
0 3 tubular  15  
1  460  medullary  2  
2 76  others  3 
x 1  EIC-status  
 
N-Stage 
 
negative 482 
0 467 positive 58 
1 71 Grade 
 
x 2 G1 146 
Resection status 
 
G2 305 
R0 540 G3 89 
Resection 
margins mm 
median 5(0.5-30) 
Her 2-neu 
Status  
Multifocality 
 
neg 483 
no 462 pos 57 
yes 78 HR-Status 
 
  
neg 43 
  
pos 497 
 
Conclusions: Tolerance of combined IOERT/hypofractionated 
WBI regimen is excellent, acute reactions moderate and late 
reactions insignificant in short-term assessment. With regard 
to postoperative appearance, early cosmetic results are not 
impaired. Both tumor control and cosmetic outcome have to 
be evaluated on long-term follow-up.  
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Purpose/Objective: The hypothesis is that partial breast 
irradiation after lumpectomy will have less impact on QoL, 
when compared to whole breast irradiation. We don’t know 
the impact of the different partial breast irradiation 
techniques. We therefore compared the QoL parameters 'pain 
and fatigue' for external beam APBI and IORT in our phase 2 
(feasibility) study. 
Materials and Methods: Eligible patients were women aged 
60 years or older with unilateral breast cancer with tumor 
stage Tis, T1 or T2 less than 3 cm treated within the context 
of a phase II study. For practical reasons using external beam 
APBI in one hospital, 10 daily fractions of 3.85 Gy, and IORT 
in the other hospital, 23.3 Gy in one fraction with electrons 
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(ELIOT). Both APBI and IORT patients have been followed 
prospectively with the same QoL questionnaires: 1 week, 3 
months, 6 months and yearly after breast conserving 
treatment.  
Results: In November 2014 the IORT part of the study 
accrued 192 patients; the APBI part 86 patients. The overall 
response for the QoL questionnaires was 82–98% at the 
different time points. 
There is a non-significant (ns) difference in pain score (VAS 1-
10) 1 week after surgery in favor of APBI patients. After 
completion of radiotherapy this difference is significant in 
favor of the APBI patients, maybe due to wound healing in 
the 4 to 5 weeks after breast conserving surgery. In time this 
difference changes, resulting in a significant difference in 
favor of IORT at 3 and 6 months. 
For fatigue (EORTC C30) the results are comparable; more 
patients are tired (ns) just after surgery for IORT, but again 
less tired at 6 and 12 months. In the explorative analysis, so 
far, co morbidity, not age, seems to influence fatigue. 
Correcting for co morbidity fatigue at 6 and 12 months is 
significant better for IORT. 
 
Mean QoL  
score 
1 week  
after surg 
IORT/APBI 
After RT 
APBI 
3 month 
IORT/APBI 
6 month 
IORT/APBI 
1 year 
IORT/APBI 
IORT pain 2.8   1.9 * 1.8 *  1.7 
APBI pain 2.5  2.2 * 2.6 2.5 2.2 
IORT fatigue 35  25 23** 21** 
APBI fatigue 28 30 26 26  26  
* significant less pain (VAS 1-10);  
** significant less fatigue, when corrected for age and comorbidity (EORTC C30) 
 
Conclusions: This preliminary analysis shows a significant 
better result for pain and fatigue for IORT compared to 
external beam APBI in the first year of follow up. An update 
of the results will be presented including the analysis of the 
confounding factors. 
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Purpose/Objective: To evaluate retrospectively survival and 
local control rates (LCR) of triple negative breast cancer 
(TNBC) subtypes classified in five marker negative (5-NP) and 
core basal (CB) after breast conserving surgery (BCS) and 
intraoperative radiotherapy with electrons (IOERT). 
Materials and Methods: 71 TNBC patients were enrolled. All 
patients were treated with BCS, axillary lymph node 
dissection and received IOERT with a median dose maximum 
of 9.6 Gy as anticipated tumorbed boost, which was followed 
by whole breast irradiation (WBI) to median total doses of 54 
Gy (range 51-57.6) in normofractionation (1.6 - 1.85 Gy 
(5Fx/week). Chemotherapy was applied neoadjuvant (12%), 
adjuvant (75%) or in combination (7%). 
Results: After a median follow-up of 97 months (range 4-170) 
5 ipsilateral breast tumor recurrences (IBTR) were detected 
(7.0%). 8-year actuarial rates of all TNBC patients for local 
control (LCR), metastases free survival (FFM), disease 
specific survival (DSS), and overall survival (OS) amount 91%, 
75%, 80%, and 69%, respectively. Subgroupanalyses revealed a 
trend of inferior outcome for CB in DSS if compared to 5-NP 
(5-NP:83% vs CB:54% for G1/G2, p=0.27, 5-NP:90% vs CB: 79% 
for G3 tumors, p=0.30 and 5-NP G3: 90% vs CB G1/2: 54%, 
p=0.03), whereas LCR seemed to be negative influenced by 
tumor grading G3 (G1/2 (CB and 5-NP):100% vs G3: 88% (5-
NP) and 90% (CB), p=0.65 and 0.82), both without statistical 
significance. 
Conclusions: IOERT as boost modality during BCT of TNBC, 
provides acceptable LCR. CB-subtype and tumorgrading G3 
are negative predictors for survival and LCR, respectively.  
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Purpose/Objective: The aim of the study was to report 
effectiveness, quality of life, toxicity, cosmetic outcomes 
and physical parametres of intraoperative radiotherapy 
(IORT) given as a boost during breast conserving surgery (BCS) 
followed by adjuvant whole breast radiotherapy (WBI).  
Materials and Methods: Between 2008 and 2011 in 150 breast 
cancers patients treated in our centre intraoperative 
radiotherapy as a tumor bed boost was applied using mobile 
electron accelerator Mobetron 1000 (IntraOp Medical, Inc.). 
IORT boost (10 Gy) was followed by 50 Gy whole-breast 
external beam radiotherapy (EBRT). Chemotherapy, if 
indicated, was given before EBRT. The observation period 
was 1,5-5,5 years. 
Clinical outcomes was assessed by physical examination, 
photos of the breast with Harris-Limbergen scale, EORTC 
questionnaires (QLQ-C30 and QLQ-BR23), analysis of acute 
and late toxicity (CTCAE v 3.0 and LENT-SOMA scales), 
mammography, ultrasounds and chest X-ray. 
Results: There was no local recurrences. Acute skin reactions 
in grade 1 and 2 were observed in 31% of pts in 1 month post 
RT and 9% in 6 months post RT, with no acute and late 
toxicities in grade 3 and 4. 
The cosmetic outcome was good to excellent in 81,5% of pts 
1 month post RT and 87% 3 years post RT. 
Pain in breast was observed in 53 % pts 1 month post RT and 
21% 6 months posr RT, hyperesthesia of the skin in 17,0 % pts. 
The data was tested with Mantel-Haenschel test. There was 
no statistical significance.  
The late toxicity was evaluated one year after radiation 
therapy. The edema of breast was reported by 18 % of pts.  
The telangiectasia of breast skin has occurred in 25 % of pts. 
Retraction of the breast occurred in 39% of pts. Fibrosis was 
detected in 60% of patients. 
There was no statistical significance change in quality of life 
in any follow-up period based on Friedman test analysis 
(p=0,2143). 
Patients were treated using all available electron beam 
energies: 6 MeV energy was used in 58% cases but also 9 MeV, 
